Compugen To Present New Clinical And Pre-Clinical Data In Multiple Presentations At SITC 2023
Portfolio Pulse from Benzinga Newsdesk
Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company, announced it will present new clinical and pre-clinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2023. The presentations will support Compugen's vision to extend the reach of cancer immunotherapies to new patient populations.
September 27, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen's announcement to present new clinical and pre-clinical data at SITC 2023 could potentially boost investor confidence in the company's research and development capabilities.
The announcement of new clinical and pre-clinical data presentations at a major conference like SITC indicates progress in Compugen's research and development efforts. This could potentially boost investor confidence in the company's capabilities and future prospects, leading to a positive impact on the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100